Besins Healthcare Germany GmbH

What Besins Healthcare Germany GmbH does

Besins Healthcare Germany GmbH is the German operating subsidiary of the family-owned Besins Healthcare group, headquartered at Mariendorfer Damm 3, 12099 Berlin in the Ullsteinhaus, with approximately 90 employees in Germany as part of a global group of around 1,500 employees spanning 22 subsidiaries across 114 countries and five GMP-certified production facilities (Montrouge, Drogenbos, Muel, Yaroslavl, Jundiaí). The German entity was formalized as an independent subsidiary in 2021 after operating as a joint venture since 1992. The group traces its origins to 1885 in Paris and is now in its fifth generation of family ownership under Co-CEOs Nicolas and Alexandre Besins.

The company develops, manufactures, and markets prescription bioidentical hormone therapies across two therapeutic areas: women's health (menopausal hormone therapy via transdermal estradiol gels and oral estradiol/progesterone combinations, oral contraceptives, fertility support including luteal-phase progesterone and ganirelix injection, and estriol products for urogenital atrophy) and men's health (testosterone replacement via the Testogel/AndroGel transdermal gel range in multiple dosages and metered-dose formats, plus injectable testosterone undecanoate). Core technology centers on proprietary transdermal gel delivery of bioidentical estradiol, testosterone, and progesterone — the company introduced the world's first progesterone gel in 1972 and the first estradiol gel for menopausal symptoms in 1975. Following the July 2026 acquisition of UniD Manufacturing (now Besins Healthcare PharmTech, Seraing, Belgium), the technology base extends to polymer-based long-acting drug delivery systems including implants and vaginal rings.

The business model is B2B prescription pharmaceutical sales: products are sold into German pharmacies and reimbursed by statutory (GKV) and private (PKV) health insurers when prescribed by physicians. Go-to-market combines an outside field sales force (Außendienst) with Medical Science Liaisons engaging gynecologists, urologists, and general practitioners, supported by a medical info hotline (0800 000 4507), congress and webinar medical education (PREIS School, IMS, PRISM, AReA), and patient-facing DTC platforms (wechseljahre-verstehen.de, mannvital.de, testocheck.de). Group revenue exceeded €700 million in 2025 with sustained double-digit growth over the past 10 years; the German subsidiary's revenue is not separately disclosed.

Name

Besins Healthcare Germany GmbH

Legal name

Besins Healthcare Germany GmbH

Website

https://besins-healthcare.de

Company type

Private

Founded year

1885

Operating status

Operating

Headcount range

51–100 employees

Short description

Besins Healthcare Germany GmbH is the Berlin-based German subsidiary of family-owned Besins Healthcare (founded 1885, Paris), developing and distributing prescription bioidentical hormone therapies — transdermal gels, oral contraceptives, and injectables — for women's menopause/fertility care and men's testosterone replacement, dispensed via German pharmacies and reimbursed by GKV and PKV insurers.

Ownership category

akta.pro rank

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical product sales (prescription hormone therapies): The company generates revenue through the sale of prescription hormone therapy products across two main therapeutic areas: women's health (menopausal hormone therapy, fertility treatments, contraception) and men's health (testosterone replacement therapy). Products are sold to healthcare providers and dispensed through pharmacies. Revenue is derived from product sales to statutory and private health insurers in Germany, with the company reporting over 700 million euros in global revenue in 2025.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

Besins Healthcare Germany GmbH develops, manufactures, and distributes prescription pharmaceutical hormone therapies in Germany, focusing on bioidentical hormones for women's health (menopausal hormone therapy, contraception, fertility treatments) and men's health (testosterone replacement therapy). The portfolio includes transdermal gels, oral contraceptives, micronized progesterone capsules, and injectable testosterone formulations, sold to physicians and dispensed through pharmacies with reimbursement from statutory and private health insurers.

Product overview

Besins Healthcare Germany GmbH is a family-owned pharmaceutical company specializing in the development and manufacturing of modern hormone preparations (bioidentical hormones) for both women and men. The product portfolio spans two main therapeutic areas: Women's Health (including combined oral contraceptives such as Minette®, Finic®, and Femikadin®; menopause hormone therapy including Cliovelle®, Gynokadin® tablets, OeKolp® estriol products, and Progestan® progesterone capsules; fertility treatments including Utrogest® Luteal progesterone capsules and Ganiran® ganirelix injection; and the Progesterone gel Progestogel®) and Men's Health (including the Androgel®/Testogel® transdermal testosterone gel range in multiple dosages/sachet forms and metered-dose gel, as well as Testosteron Besins® testosterone undecanoate injection). The company operates as a B2B pharmaceutical manufacturer and distributor, serving healthcare professionals and patients through prescription-based products distributed via pharmacies in Germany. Besins Healthcare Germany is a subsidiary of the global Besins Healthcare group (founded 1885, Paris) with 22 subsidiaries and 5 production facilities worldwide, and operates its own dedicated patient-facing informational websites (e.g., testocheck.de, mannvital.de, wechseljahre-verstehen.de) alongside its core product portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• HORMONSPEZIALISTEN.de: Information and continuing education platform for physicians on the topic of sexual hormones
• Mannvital.de
• Testogel.de
• Wechseljahre-Verstehen.de

Products and services

• Testosteron Besins 1000 mg/4 ml Injection solution containing testosterone undecanoate for the treatment of male hypogonadism (testosterone deficiency) in men.
• Testogel 50 mg transdermales Gel im Beutel Transdermal testosterone gel (50 mg per sachet) for topical application to the skin, used in testosterone replacement therapy for men with hypogonadism.
• Testogel 40,5 mg transdermales Gel im Beutel Transdermal testosterone gel (40.5 mg per sachet) for topical application in testosterone replacement therapy.
• Testogel Dosiergel 16,2 mg/g Gel Metered-dose testosterone transdermal gel (16.2 mg/g) for application to the skin in testosterone replacement therapy for men.
• Minette 2 mg/0,03 mg Mikropille Combined oral contraceptive micropill containing 0.03 mg ethinylestradiol and 2 mg chlormadinone acetate, for hormonal contraception in women.
• Ladivella 1 mg/2 mg Tabletten Tablet formulation containing 1 mg estradiol valerate and 2 mg dienogest, used in women's health hormone therapy.
• Finic 0,03 mg/2 mg Mikropille Combined oral contraceptive micropill containing 0.03 mg ethinylestradiol and 2 mg dienogest.
• Femikadin 20/30 Combined oral contraceptive micropill available in two dosage strengths: Femikadin 20 (0.02 mg ethinylestradiol / 0.1 mg levonorgestrel) and Femikadin 30 (0.03 mg ethinylestradiol / 0.15 mg levonorgestrel).
• Cliovelle 1 mg/0,5 mg Tabletten Tablet containing 1 mg estradiol and 0.5 mg norethisterone acetate, used in hormone replacement therapy for women.
• Utrogest Luteal 200 mg/300 mg Weichkapseln Soft vaginal capsules containing micronized progesterone (200 mg and 300 mg) for luteal phase support, fertility treatment, and hormone replacement therapy.
• Ganiran 0,25 mg/0,5 ml Injektionslösung Injection solution in a pre-filled syringe containing 0.25 mg ganirelix in 0.5 ml aqueous solution, used in fertility treatment to prevent premature ovulation.
• Gynokadin Tabletten 2 mg Oral tablets containing 2 mg estradiol valerate, used in hormone replacement therapy for women during and after menopause.
• Progestogel 10 mg/g Gel Progesterone gel (1%) for transdermal application, containing 10 mg/g micronized progesterone.
• OeKolp Ovula, Creme, Tabletten Estriol-containing vaginal suppositories (Ovula 0.5 mg and 0.03 mg), vaginal cream (1 mg/g estriol), and oral tablets (2 mg estriol) for the treatment of vaginal and urogenital symptoms related to estrogen deficiency.
• Progestan 100 mg Weichkapseln Soft oral capsules containing micronized progesterone (100 mg), used in hormone replacement therapy and fertility treatment.

Quantifiable outcome

• Approximately 9.4 billion euros in annual economic damage to the German economy from untreated menopausal symptoms (equivalent to nearly 40 million lost workdays), highlighting the societal value of proper hormonal treatment.
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, minor and major.

• UniD Manufacturing (acquired and renamed Besins Healthcare PharmTech)coreStrategic or Co-development Partner · 2 July 2026Besins Healthcare acquired UniD Manufacturing on July 2, 2026, renaming it Besins Healthcare PharmTech. UniD is a Belgian pharmaceutical development and manufacturing company with over 20 years of recognized expertise in long-acting drug release technologies and advanced polymer-based pharmaceutical formulations. UniD operates at its Seraing, Belgium facility with 52 highly skilled employees and will serve as a strategic innovation center within Besins Healthcare while continuing to serve its existing customers.
• Isabelle and Audrey (Women's Health Ambassadors)minorGTM or Marketing Partner · 1 January 2024Isabelle and Audrey, connected by 18 years of friendship and adventure, are ambassadors for women's health supporting Besins Healthcare. They participated in the Rallye Aïcha des Gazelles in Morocco (April 2024) driving an electric buggy, embodying the company's values of solidarity, empowerment, and ecological responsibility.
• International Menopause Society (IMS)majorStrategic or Co-development Partner · 1 January 2020Besins Healthcare sponsors the monthly IMS webinars since 2020 with an unrestricted educational grant, providing healthcare professionals with high-scientific and clinically relevant current information on women's health during various phases of menopause. The company also supports IMS congress participation.
• PREIS School (International and European School of Perinatal, Neonatal and Reproductive Medicine)majorStrategic or Co-development Partner · 1 January 2013Besins Healthcare has financed 136 courses organized through the PREIS School since 2013, with an average of 460 participants per year from 42 different countries. Courses are led by 62 expert lecturers and held worldwide (New York, Mexico City, Buenos Aires, Detroit, Athens, Venice, St. Petersburg, Rome, Beijing, Sydney, Dubai, Berlin, Bangkok). The partnership aims to advance perinatal, neonatal, and reproductive healthcare standards globally.
• Tour der HoffnungminorGTM or Marketing Partner · 1 January 2005Since 2005, Besins Healthcare has been an official partner of the nationwide 'Tour der Hoffnung' (Tour of Hope), a charity bicycle tour for children with leukemia. The 40th Tour in 2023 raised 1,715,700 euros for institutions dedicated to cancer research, new therapy concepts, and nursing, psychological, and social care for sick children and their families.
• PRISM (Postgraduate International School of Men's Health)majorStrategic or Co-development PartnerPRISM is a renowned center of excellence dedicated to interdisciplinary education in men's health. Besins Healthcare supports healthcare professionals' participation in PRISM programs, ensuring access to the latest research findings and clinical practices in men's health. This partnership affirms the company's commitment to advancing men's health education and improving healthcare outcomes for patients.
• Andrology Research Academy (AReA)coreStrategic or Co-development PartnerAReA is a virtual forum and center of excellence in men's health that facilitates top-tier research and collaboration among researchers and medical professionals worldwide, with over 1,000 registered users from more than 45 countries. Besins Healthcare serves as a scientific partner, sponsoring virtual seminars, webinars, and symposia organized by AReA to advance the scientific exchange of knowledge and expertise in men's health.
• Kinderprojekt Die ArcheminorGTM or Marketing PartnerBesins Healthcare supports the 'Kinderprojekt Die Arche' (Children's Project The Ark), a social initiative that sees it as its responsibility to draw attention to social disadvantages in society and advocate for lasting improvements in the living conditions of disadvantaged children and families in Germany.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Market position

Weaknesses5 records

Competitive moat6 records

Customer concentration

• Xxing.com/pages/besinshealthcaregermanygmbh
• YouTubeyoutube.com/@besinshealthcaregermany6554
• LinkedInlinkedin.com/company/besins-healthcare-germany

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Besins Healthcare Germany GmbH